Azitra Inc (AZTR)

Name: Azitra Inc (AZTR) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Azitra Inc (AZTR)

Stock Card

$0.18

$-0.03 (-13.28%)

As on 28-Aug-2026 16:22EDT

Market cap

$8 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

6.6

P/B Ratio

0.3

Div. Yield

0 %

Azitra Inc (AZTR) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 0.17 High: 0.19

52 Week Range

Low: 0.10 High: 1.09

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-2.6 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-0.4
Debt to Equity

0
Book Value

$--
EPS

$-1.6
Face value

--
Shares outstanding

60,603,742

Years Aggregate

CFO

$--

EBITDA

$--

Net Profit

$--

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Azitra Inc (AZTR)	-33.2	--	-13.3	-82.8	-92.4	--	--
BSE Sensex	-8.8	0.6	1.8	-4.4	6.0	6.6	10.8
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 28-Aug-2026 | #As on 26-Oct-2023

Company	2025	2024
Azitra Inc (AZTR)	-90.6	-98.4
S&P Small-Cap 600	4.0	7.0
BSE Sensex	9.1	8.1

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Azitra Inc (AZTR)	0.2	8.1	0.0	-12.3	--	-220.4	6.6	0.3
DBV Technologies S.A. - ADR	13.5	914.4	0.0	-175.9	--	-106.8	--	5.6
HUTCHMED (China) - ADR	12.4	2,151.8	549.1	17.9	-6.3	1.4	123.8	1.7
Inventiva Sa (IVA)	4.7	1,105.5	4.5	-340.2	-518.6	501.4	--	2.1
LogicBio Therapeutics (LOGC)	12.8	587.5	0.0	-29.0	0.0	-20.4	--	2.0
Mesoblast - ADR	17.4	2,204.8	65.4	-94.4	-108.2	-16.1	--	3.9
Pharming Group N.V. ADS each representing 10 (PHAR)	11.7	838.7	366.5	9.3	8.3	3.4	84.6	3.1
Prime Medicine	3.6	654.8	4.1	-187.9	-4,613.1	-233.9	--	0.3
Silence Therapeutics PLC (SLN)	13.4	824.8	0.6	-59.9	-9,892.6	-118.9	--	21.3
Zai Lab - ADR	26.1	2,920.0	449.6	-188.2	-41.1	-28.5	--	4.8

Shareholding Pattern

View Details

About Azitra Inc (AZTR)

Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04,... a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S. epidermidis, which is in a Phase 1b/2a clinical trial for treating Netherton syndrome, a skin disease; and ATR-01, a genetically modified strain of S. epidermidis that expresses an engineered recombinant human filaggrin protein, which is in the IND-enabling phase for treating ichthyosis vulgaris, a skin disease. It has a joint development agreement with Bayer for the identification and characterization of S. epidermidis strains for topical formulations. Azitra, Inc. was incorporated in 2014 and is headquartered in Branford, Connecticut. Read more

President, CEO & Director

Mr. Francisco D. Salva
Co-Founder, COO, Secretary & Director

Dr. Travis M. Whitfill M.P.H., Ph.D.
Headquarters

Branford, CT
Website

https://azitrainc.com

FAQs for Azitra Inc (AZTR)

What is the current share price of Azitra Inc (AZTR) Today?

The share price of Azitra Inc (AZTR) is $0.18 (NYSE) as of 28-Aug-2026 16:22 EDT. Azitra Inc (AZTR) has given a return of -92.38% in the last 3 years.

What is the current PB & PE ratio of Azitra Inc (AZTR)?

The P/E ratio of Azitra Inc (AZTR) is 6.64 times as on 21-Aug-2026.
The P/B ratio of Azitra Inc (AZTR) is 0.28 times as on 21-Aug-2026, a 94 discount to its peers’ median range of 4.82 times.

PE & PB ratio at the end of financial year.